In a report released yesterday, Josh Silverstein from UBS maintained a Hold rating on Patterson-UTI, with a price target of $13.00. Silverstein covers the Energy sector, focusing on stocks such as Baker Hughes Company, Halliburton, and SLB. According to TipRanks, Silverstein…
Barclays analyst Luke Sergott maintained a Sell rating on Avantor today and set a price target of $15.00. Sergott covers the Healthcare sector, focusing on stocks such as Bruker, Danaher, and Illumina. According to TipRanks, Sergott has an average return of…
Piper Sandler analyst David Amsellem maintained a Buy rating on Biogen today and set a price target of $245.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 13.8% and a 58.33% success rate. Amsellem covers the Healthcare sector,…
The latest announcement is out from Avnet ( (AVT) ). The most recent analyst rating on (AVT) stock is a Sell with a $80.00 price target. To see the full list of analyst forecasts on Avnet stock, see the AVT Stock Forecast page.
Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Amgen today and set a price target of $440.00. Gould covers the Healthcare sector, focusing on stocks such as Amgen, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Gould has…
Ultra Clean Holdings ( (UCTT) ) just unveiled an announcement. The most recent analyst rating on (UCTT) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Ultra Clean Holdings stock, see the UCTT Stock…
Biodexa Pharmaceuticals ( (BDRX) ) has provided an update. Spark’s Take on BDRX Stock According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral. Overall score is held down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn)…
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Pfizer, with a price target of $33.00. Chen covers the Healthcare sector, focusing on stocks such as AbbVie, Johnson & Johnson, and Amgen. According to TipRanks, Chen has…
The latest update is out from Verra Mobility ( (VRRM) ). On September 30, 2026, Verra Mobility’s board appointed veteran mobility and transportation executive Jon Newhard as president and chief executive officer, effective November 1, 2026. The board also expanded its size from six to seven…
In a report released today, Daniel Clark from Leerink Partners reiterated a Buy rating on Amneal Pharmaceuticals, with a price target of $23.00. According to TipRanks, Clark is a 3-star analyst with an average return of 9.0% and a 56.00% success rate. Clark…
Hospitals, clinics, payers, med‑tech, telehealth, and healthcare services delivery.
An article joins this feed when it matches these terms. Each one is also a search of its own.